A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-01-29
Adverse events
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-19 (study day 6); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-18 (study day 33); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-07 (study day 83); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 140); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-07-09 (study day 146); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-07 (study day 175); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-08 (study day 207); relationship: not assessed
Data queries
No data queries.